Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMT Research Partners with ReviR to Advance Small Molecule Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReviR Therapeutics Reaches Milestone in Splicing Therapy Development with Asieris","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReviR Therapeutics Raises $30M Series A to Oral Genetic Medicines for CNS Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by ReviR Therapeutics

    Menu

    ReviR Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ReviR Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ReviR Therapeutics Raises $30M Series A to Oral Genetic Medicines for CNS Disorders

              Details:

              The funds will be used to advance ReviR's AI-driven drug discovery VoyageR platform, which will be leveraged to advance the clinical development of treatments for Huntington's disease.

              Lead Product(s): Undisclosed

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Lapam Capital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Series A Financing July 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ReviR Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CMT Research Partners with ReviR to Advance Small Molecule Therapeutics

              Details:

              The partnership with ReviR Therapeutics aligns perfectly with CMTRF's mission to accelerate the development of therapies for treating Charcot-Marie-Tooth disease.

              Lead Product(s): Undisclosed

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: CMT Research Foundation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership June 19, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ReviR Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ReviR Therapeutics Reaches Milestone in Splicing Therapy Development with Asieris

              Details:

              Asieris will be utilizing ReviR's innovative RNA modulation Platform Technologies, named BindeR and SpliceR, to identify and develop new therapeutics that target RNA to treat cancer.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Asieris Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 17, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ReviR Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies

              Details:

              In the agreement, Asieris will be utilizing ReviR's innovative RNA modulation Platform Technologies, named BindeR and SpliceR, to identify and develop new therapeutics (SMALL MOLECULES) that target RNA to treat cancer.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Asieris Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement February 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY